Sun Pharmaceutical Industries Ltd. reported that in Q2 FY26, its innovative medicines outpaced generic drug sales in the United States, marking a strategic shift in its business mix. Strong demand for key products, including Ilumya (psoriasis), Cequa (dry eye disease), and Odomzo (skin cancer), drove this performance.
Boost from New Launches
The July launch of Leqselvi, a newly approved alopecia treatment, further accelerated growth. Sun Pharma acquired the product through its $576 million purchase of Concert Pharma. Sun Pharma rolled out the product after settling with Incyte Corp., and it has been well received in the U.S. market. Richard Ascroft, CEO of Sun Pharma’s North America business, noted, “By Q3 and Q4, sales of innovative medicines will continue to rise as we prepare to launch our cancer immunotherapy Unloxcyt.”
Strong Growth in Innovative Medicine Revenue
Global innovative drug revenue reached $333 million in Q2FY26, up 16.4% YoY, accounting for 20.2% of total consolidated revenue. For the first half of FY26, innovative drug sales totalled $644 million, growing 16.6% YoY.
Future Outlook: R&D and Regulatory Milestones
Executive Chairman Dilip Shanghvi reaffirmed the company’s focus on expanding its R&D pipeline. He added that Sun Pharma is awaiting updated FDA labeling approval for Unloxcyt, ahead of its planned U.S. launch in the second half of FY26. As reported by indiapharmaoutlook.com, Sun Pharma is continuing to shift toward innovative and specialty medicines. This strategy positions the company to strengthen margins and enhance market differentiation. It also helps secure long-term growth in the U.S. and global pharmaceutical markets.
